Adagio Medical Holdings, Inc. (ADGM)
NASDAQ: ADGM · Real-Time Price · USD
0.926
+0.035 (3.97%)
At close: Dec 5, 2025, 4:00 PM EST
0.938
+0.012 (1.30%)
After-hours: Dec 5, 2025, 7:52 PM EST
Company Description
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias.
It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia.
The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories.
Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Adagio Medical Holdings, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Todd Usen |
Contact Details
Address: 26051 Merit Circle, Suite 102 Laguna Hills, California 92653 United States | |
| Phone | 949 348 1188 |
| Website | adagiomedical.com |
Stock Details
| Ticker Symbol | ADGM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002006986 |
| CUSIP Number | 00534B100 |
| ISIN Number | US00534B1008 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Todd Usen | Chief Executive Officer and Director |
| Olav B. Bergheim | Advisor |
| Deborah Kaster | Chief Financial Officer and Chief Business Officer |
| Dr. Alex Babkin Ph.D. | Chief Technical Officer |
| Nabil Jubran | Chief Compliance Officer |
| Ilya Grigorov | Vice President of Global Marketing and Product Management |
| Maryline Cullen | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 24, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 13, 2025 | SCHEDULE 13G/A | Filing |
| Nov 12, 2025 | 424B3 | Prospectus |
| Nov 12, 2025 | 424B3 | Prospectus |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 4, 2025 | ARS | Filing |
| Nov 4, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 29, 2025 | D | Notice of Exempt Offering of Securities |
| Oct 24, 2025 | 424B3 | Prospectus |